Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer

被引:2
|
作者
Jurj, Ancuta [1 ]
Zanoaga, Oana [1 ]
Raduly, Lajos [1 ]
Morhan, Vlad [2 ]
Papi, Zsofia [3 ]
Ciocan, Cristina [1 ]
Pop, Laura-Ancuta [1 ]
Berindan-Neagoe, Ioana [1 ]
Braicu, Cornelia [1 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom, Biomed & Translat Med, Cluj Napoca 400347, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Cluj Napoca 400347, Romania
[3] Univ Szeged, Fac Med, H-6720 Szeged, Hungary
关键词
miR-29b-3p inhibitor; triple-negative breast cancer; miRNA; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; CELLS; EXPRESSION; GROWTH;
D O I
10.3390/ijms24055048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lack of estrogen or progesterone receptors and absence of HER2 amplification/overexpression in triple-negative breast cancer (TNBC) restricts therapeutic options used in clinical management. MicroRNAs (miRNAs) are small, non-coding transcripts which affect important cellular mechanisms by regulating gene expression at the post-transcriptional level. Among this class, attention was focused on miR-29b-3p with a high profile in TNBC and correlated with the overall survival rates, as TCGA data revealed. This study aims to investigate the implication of the miR-29b-3p inhibitor in TNBC cell lines by identifying a potential therapeutic transcript, improving the clinical outcomes of this disease. The experiments were performed on two TNBC cell lines (MDA-MB-231 and BT549) as in vitro models. An established dose of 50 nM was used for all functional assays performed on the miR-29b-3p inhibitor. A decreased level of miR-29b-3p determined a significant reduction in cell proliferation and colony-forming capacity. At the same time, the changes occurring at the molecular and cellular levels were highlighted. We observed that, when inhibiting the expression level of miR-29b-3p, processes such as apoptosis and autophagy were activated. Further, microarray data revealed that the miRNA expression pattern was altered after miR-29b-3p inhibition, pointing out 8 overexpressed and 11 downregulated miRNAs specific for BT549 cells and 33 upregulated and 10 downregulated miRNAs that were specific for MDA-MB-231 cells. As a common signature for both cell lines, three transcripts were observed, two downregulated, miR-29b-3p and miR-29a, and one upregulated, miR-1229-5p. According to DIANA miRPath, the main predicted targets are related to ECM (extracellular matrix) receptor interaction and TP53 signaling. An additional validation step through qRT-PCR was performed, which showed an upregulation of MCL1 and TGFB1. By inhibiting the expression level of miR-29b-3p, it was shown that complex regulatory pathways targeted this transcript in TNBC cells.
引用
下载
收藏
页数:16
相关论文
共 50 条
  • [41] NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer
    Nagamatsu, Iori
    Onishi, Hideya
    Matsushita, Shojiro
    Kubo, Makoto
    Kai, Masaya
    Imaizumi, Akira
    Nakano, Kenji
    Hattori, Masami
    Oda, Yoshinao
    Tanaka, Masao
    Katano, Mitsuo
    ANTICANCER RESEARCH, 2014, 34 (1A) : 69 - 80
  • [42] Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
    Li, Ying
    Zhan, Zhijun
    Yin, Xuemin
    Fu, Shujun
    Deng, Xiyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] New Therapeutic Strategies for Triple-Negative Breast Cancer
    Szekely, Borbala
    Silber, Andrea L. M.
    Pusztai, Lajos
    ONCOLOGY-NEW YORK, 2017, 31 : 13 - 20
  • [44] New Therapeutic Strategies for Triple-Negative Breast Cancer
    Szekely, Borbala
    Silber, Andrea L. M.
    Pusztai, Lajos
    ONCOLOGY-NEW YORK, 2017, 31 (02): : 130 - 137
  • [45] Therapeutic targets of triple-negative breast cancer: a review
    Jamdade, Vinayak S.
    Sethi, Nikunj
    Mundhe, Nitin A.
    Kumar, Parveen
    Lahkar, Mangala
    Sinha, Neeraj
    BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (17) : 4228 - 4237
  • [46] Promising therapeutic options in triple-negative breast cancer
    Bilici, A.
    Arslan, C.
    Altundag, K.
    JOURNAL OF BUON, 2012, 17 (02): : 209 - 222
  • [47] Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
    Mahtani, Reshma
    Kittaneh, Muaiad
    Kalinsky, Kevin
    Mamounas, Eleftherios
    Badve, Sunil
    Vogel, Charles
    Lower, Elyse
    Schwartzberg, Lee
    Pegram, Mark
    CLINICAL BREAST CANCER, 2021, 21 (05) : 383 - 390
  • [48] Triple-negative breast cancer: MRI features in 29 patients
    Chen, J. -H.
    Agrawal, G.
    Feig, B.
    Baek, H. -M.
    Carpenter, P. M.
    Mehta, R. S.
    Nalcioglu, O.
    Su, M. -Y.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 2042 - 2043
  • [49] The oncogenic role of miR-150-5p in triple-negative breast cancer
    Sugita, Bruna M.
    Zabala, Yara
    Fonseca, Aline
    Almeida, Rodrigo
    Gusev, Yuriy
    Boca, Simina
    Cavalli, Iglenir J.
    Ribeiro, Enilze M.
    Cavalli, Luciane R.
    CANCER RESEARCH, 2017, 77
  • [50] Targeting the Vav1/miR-29b axis as a potential approach for treating selected molecular subtypes of triple-negative breast cancer
    Grassilli, Silvia
    Vezzali, Federica
    Cairo, Stefano
    Brugnoli, Federica
    Volinia, Stefano
    De Mattei, Monica
    Judde, Jean-Gabriel
    Bertagnolo, Valeria
    ONCOLOGY REPORTS, 2021, 45 (05)